Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study

Short-acting β(2)-agonist (SABA) use is known to be lower in Korean patients with asthma than in those from other countries, while the rate of asthma exacerbations in Korea is higher than in other countries. Thus, an epidemiologic study on SABA use and the relationship between SABA overuse and treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun, Ryu, Jiin, Chung, Sung Jun, Yeo, Yoomi, Park, Tai Sun, Park, Dong Won, Moon, Ji-Yong, Kim, Tae-Hyung, Sohn, Jang Won, Yoon, Ho Joo, Kim, Sang-Heon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569021/
https://www.ncbi.nlm.nih.gov/pubmed/34734512
http://dx.doi.org/10.4168/aair.2021.13.6.945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569021/
https://www.ncbi.nlm.nih.gov/pubmed/34734512
http://dx.doi.org/10.4168/aair.2021.13.6.945

Ejemplares similares